Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 13, 2024
Discovery & Translation
Science Spotlight: How extrachromosomal DNA drives cancer
BioCentury’s roundup of translational innovation features two trios of papers: one on genetic control of cancer and the other on MASLD markers
BioCentury | Jun 26, 2024
Discovery & Translation
Lurie winner Chang: Translating the unexpected in gene regulation
A Q&A with the serial entrepreneur, who was awarded FNIH’s Lurie Prize for his lncRNA
BioCentury | Apr 12, 2024
Finance
Public equity report: Acrivon refreshes balance sheet with $130M PIPE
Plus Eliem, Century raise private placements as they make acquisitions; Nurix’s AACR readout precedes follow-on; Skye uplists
BioCentury | Mar 28, 2024
Finance
Venture report: Liquidity coming for Boundless’ syndicate; plus Avenzo’s $150M round
As VC-backed start-ups continue to watch and wait for their IPO window, a large syndicate backs an oncology start-up with aspirations to go public
BioCentury | Mar 22, 2024
Finance
Public equity report: Galderma rises after $2B IPO; Contineum, Boundless prep U.S. listings
Plus Madrigal’s follow-on is among the year’s largest, and PureTech returns cash to shareholders following Karuna takeout
BioCentury | Mar 9, 2024
Finance
Public equity report: Boundless to test IPO appetite as follow-ons continue to deliver
Public offerings by Akero, BridgeBio, RegenxBio, Apogee, plus PIPEs for Ventyx and BiomX-Adaptive Phage union
BioCentury | Jul 31, 2023
Management Tracks
Does Arch’s Rubin taking CFO role at Boundless signal IPO plans?
Former analyst arrived at venture firm in May after leaving EQRx
BioCentury | May 19, 2023
Discovery & Translation
Targets for severe COVID-19; plus Alzheimer’s resistance case study and more
BioCentury’s roundup of translational news
BioCentury | May 17, 2023
Finance
May 16 Quick Takes: Leaps by Bayer, RA Capital back Boundless in $100M series C
Plus: Prevail, Scribe in gene editing deal and updates from Ensoma, NewLimit and Drug Farm
BioCentury | Nov 15, 2022
Finance
Nov. 15 Quick Takes: Panacea to deploy $276M in pair of funds
Plus: Acrivon’s IPO; fundings for Bonum, CG Oncology and Jnana; and pipeline updates from Arcutis and Everest
Items per page:
1 - 10 of 72